Skip to main content
main-content

The independent medical news service

26-01-2022 | Oncology | News | Article

Radiotherapy futile add-on to durvalumab–tremelimumab in refractory NSCLC

Adding low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab offers no significant benefit to people with non-small-cell lung cancer that is resistant to PD-1 or PD-L1 inhibition, US study findings indicate.

25-01-2022 | Oncology | News | Article

ESMO–EURACAN publish guideline for testicular cancer

More details on this joint guideline here

24-01-2022 | Oncology | News | Article

Cutaneous irAEs linked to improved survival following ICI therapy

Cutaneous immune-related adverse events are associated with a reduced risk for death among cancer patients with immune checkpoint inhibitors, research suggests.

21-01-2022 | Oncology | News | Article

ASCO/Ontario Health guideline on bone-modifying agents in breast cancer updated

Click through to find out what has changed

21-01-2022 | Oncology | News | Article

Capecitabine-containing adjuvant regimen improves early breast cancer OS

Adjuvant treatment with a capecitabine-containing chemotherapy regimen could improve the overall survival of patients with early breast cancer, suggest long-term follow-up data from the phase 3 FinXX trial.

20-01-2022 | Oncology | Highlight | Article

Sugemalimab shows promise for locally advanced, metastatic NSCLC

The PD-L1 inhibitor sugemalimab has shown potential both as a consolidation treatment option for inoperable, locally advanced non-small-cell lung cancer as well as in combination with chemotherapy for the first-line treatment of metastatic disease.

19-01-2022 | Oncology | News | Article

CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC

People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma report less decline in health-related quality of life during treatment than those given sunitinib, show data from the phase 3 CheckMate 9ER trial.

18-01-2022 | Oncology | News | Article

Reassurance on radiotherapy use prior to ICI initiation

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

17-01-2022 | Oncology | News | Article

BMI may be key to unlocking metformin NSCLC benefit

A post-hoc analysis of a randomized trial points to the benefit of adding metformin to an EGFR–tyrosine kinase inhibitor in advanced non-small-cell lung cancer patients with a BMI of at least 24 kg/m2.

14-01-2022 | Oncology | News | Article

10-year cumulative false–positive mammography risk around 20%

Just under one in five women will experience at least one false–positive result during 10 years of biennial breast screening, population-based data from Norway show.

13-01-2022 | Oncology | News | Article

Meta-analysis confirms benefit of quitting smoking at lung cancer diagnosis

Quitting smoking around the time of receiving a lung cancer diagnosis is associated with significantly improved overall survival than continuing smoking, shows a meta-analysis published in the Journal of Thoracic Oncology.

12-01-2022 | Oncology | News | Article

Antibody response to COVID-19 vaccine strengthened after third dose in cancer patients

Research from three countries adds support for the use of a booster dose of vaccines against SARS-CoV-2 in people with cancer, especially those undergoing active anticancer treatment.

11-01-2022 | Oncology | News | Article

Better outcomes with radiotherapy for Black versus White prostate cancer patients

Black men with localized prostate cancer fare better than their White counterparts after definitive radiotherapy, suggests a meta-analysis.

10-01-2022 | Oncology | News | Article

GnRHa protects ovarian function during chemotherapy for breast cancer

Adding a gonadotropin-releasing hormone analog to cyclophosphamide-containing chemotherapy significantly reduces the risk for premature ovarian insufficiency in premenopausal women with breast cancer, Chinese research shows.

07-01-2022 | Oncology | News | Article

Adding camrelizumab to first-line chemo improves squamous NSCLC outcomes

Treatment-naïve patients with advanced squamous non-small-cell lung cancer derive a significant progression-free survival and overall survival benefit with the addition of camrelizumab to chemotherapy, indicates the Chinese CameL-sq study.

06-01-2022 | Oncology | News | Article

Cancer patients remain at risk for severe outcomes after breakthrough COVID-19 infection

People with cancer remain susceptible to severe outcomes after developing breakthrough SARS-CoV-2 infection despite being fully vaccinated, research suggests.

06-01-2022 | Oncology | News | Article

Advanced melanoma nivolumab–ipilimumab outcomes may be poorer in women

Women may derive less benefit from combination immune checkpoint inhibitor therapy for advanced melanoma than men, suggest study findings published in JAMA Network Open.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

05-01-2022 | Oncology | News | Article

ASCO releases guideline for stage III NSCLC management

Click through for more information

05-01-2022 | Oncology | News | Article

HRQoL data reported for ENZAMET trial of enzalutamide in metastatic HSPC

The addition of enzalutamide rather than a standard nonsteroidal anti-androgen to testosterone suppression is associated with worsening of some health-related quality of life function and symptom scores in men with metastatic hormone-sensitive prostate cancer, report the ENZAMET researchers.

04-01-2022 | Oncology | News | Article

HER2CLIMB final OS analysis confirms tucatinib HER2-positive breast cancer benefit

The addition of tucatinib to trastuzumab plus capecitabine continues to confer an overall survival benefit in advanced HER2-positive breast cancer over longer follow-up, show phase 2 data.

Image Credits